KalGene Pharmaceuticals Inc., a biotech company developing precision medicine therapeutics for effective treatment of Alzheimer’s disease, has completed second tranche of Series A, raising $#SUBSCRIBERS ONLY CONTENT Where and how did you get your news? Subscribe today to see our research on this and all other subscriber ONLY news. See what you have been missing and be informed!#
KalGene Pharmaceuticals closed its Series A in November 2017, which was led by Lumira Capital with participation from Anges Québec, Anges Québec Capital, Accel-Rx Health Sciences Accelerator and private investors.
KalGene Pharmaceuticals intends to use the funding to support the development of KalGene’s lead Alzheimer’s therapeutic candidate.
Norton Rose Fulbright Canada LLP acts as legal counsel to KalGene Pharmaceuticals.
BC/Ontario/Quebec based KalGene Pharmaceuticals is led by Dr. T. Nathan Yoganathan, President and Chief Scientific Officer, and Dr. John W. Gillard, VP of Product Development.
In 2015, KalGen raised $1.5 million from Brain Canada, CQDM, and the Ontario Brain Institute (OBI).
photo credit: KalGene Pharmaceuticals
Ted is the architect of CVCA infobase, and is the architect of CPE Media's Financings.ca, Canada's most sophisticated and advanced all private capital and public market financing database.
Latest posts by Ted Liu (see all)
- OSC releases action plan to reduce burden for market participants - November 19, 2019
- Walter Capital Partners and Bourgie-Bovet family invest in Athos Services Commémoratifs - November 19, 2019
- Steel Reef to acquire Crescent Point certain Saskatchewan assets for $500M - November 17, 2019